Companies › Xintian Pharmaceutical
1 active drug program in 1 registered trial: 1 Phase 4; Metabolic and endocrine; next expected readout Jul 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| JiRui® Prunella oral liquid Herbal preparation with purported anti-inflammatory and immunomodulatory effects | – | Phase 4 | Thyroid Nodule | Jul 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06423235 | JiRui® Prunella oral liquid | Phase 4 | Thyroid Nodule | Metabolic and endocrine | Jul 2028 |
No annotated target.
–
BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd. Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Orphalan Lumos Pharma Neuvosyn Laboratories
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.